Description

Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C74H99ClN14O16—-[1]Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7.–547741-72-0–1476.12–99.90–CC(O)=O.CC(C[C@@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@@H](C(N)=O)C)=O)=O)CCCCNC(C)C)=O)NC([C@H](NC([C@@H](N(C([C@@H](NC([C@H](NC([C@H](NC([C@H](NC(C)=O)CC2=CC=C3C=CC=CC3=C2)=O)CC4=CC=C(Cl)C=C4)=O)CC5=CN=CC=C5)=O)CO)=O)C)CC6=CC=C(O)C=C6)=O)CC(N)=O)=O)C–Cancer; Endocrinology–DMSO : ≥ 100 mg/mL|H2O : 25 mg/mL (ultrasonic)–GnRH Receptor—-GPCR/G Protein–Peptides